Antileukemic activity of an arsenomolybdate in the human HL-60 and U937 leukemia cells

• Published in: Journal of inorganic biochemistry 2017-03, Vol.168, p.67-75
• Main Authors: Li, Chunyan, Cao, Hongqian, Sun, Jiaheng, Tian, Rui, Li, Dongbei, Qi, Yanfei, Yang, Wei, Li, Juan
• Format: Article
• Language: English
• Subjects: Acute promyelocytic leukemia; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Arsenicals - chemical synthesis; Arsenicals - chemistry; Arsenicals - pharmacology; Arsenomolybdate; Blotting, Western; Caspase 3 - drug effects; Cell Cycle - drug effects; Cell Proliferation - drug effects; Drug Stability; Flow Cytometry; Fluorescence; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute - drug therapy; Molybdenum - chemistry; Molybdenum - pharmacology; Polyoxometalates; U937 Cells
• ISSN: 0162-0134; 1873-3344
• DOI: 10.1016/j.jinorgbio.2016.12.002

The antileukemic activity, mechanisms and serum albumin interactions of an arsenomolybdate, K2Na[AsMo6O21(O2CCH2NH3)3]·6H2O (1), was evaluated in the human leukemia HL-60 and U937 cells. The results indicated that 1 could inhibit the proliferation of both leukemia cell lines in a dose-dependent manner with the 50% lethal concentration (IC50) value of 8.61μM for HL-60 and 14.50μM for U937 at 24h, compare to the positive controls, all-trans retinoic acid (ATRA) with IC50 value of 20.76μM and 14.85μM,and As2O3 with IC50 value of 6.40μM and 8.75μM at 24h, respectively (P